175 related articles for article (PubMed ID: 38274805)
1. Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma.
Dai Z; Wang Y; Sun N; Zhang C
Front Immunol; 2023; 14():1299953. PubMed ID: 38274805
[TBL] [Abstract][Full Text] [Related]
2. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma.
Zhao Y; Chen C; Chen K; Sun Y; He N; Zhang X; Xu J; Shen A; Zhao S
Sci Rep; 2024 May; 14(1):12163. PubMed ID: 38806553
[TBL] [Abstract][Full Text] [Related]
4. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.
Zhang Q; Tsui YM; Zhang VX; Lu AJ; Lee JM; Lee E; Cheung GC; Li PM; Cheung ET; Chia NH; Lo IL; Chan AC; Cheung TT; Ng IO; Ho DW
Theranostics; 2024; 14(2):892-910. PubMed ID: 38169544
[No Abstract] [Full Text] [Related]
7. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
8. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
10. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
PeerJ; 2023; 11():e14691. PubMed ID: 36650832
[TBL] [Abstract][Full Text] [Related]
12. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
13. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
15. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion.
Yang J; Xing Z
Exp Biol Med (Maywood); 2021 Sep; 246(17):1928-1937. PubMed ID: 34053234
[TBL] [Abstract][Full Text] [Related]
16. Single-cell transcriptomics reveals the role of Macrophage-Naïve CD4 + T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma.
Mo Z; Liu D; Chen Y; Luo J; Li W; Liu J; Yu L; Huang B; Zhang S
J Transl Med; 2022 Oct; 20(1):466. PubMed ID: 36221095
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
18. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
19. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of SLCO4C1 as a biological marker in hepatocellular carcinoma based on anoikis classification features.
Wang T; Guo K; Yang S; Zhang D; Cui H; Yin J; Yuan S; Wang Y; Qi Y; Wu W
Aging (Albany NY); 2024 Jan; 16(2):1440-1462. PubMed ID: 38226966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
